Actavis loses Atelvia patent fight; CA high court hears pay-for-delay case;

@FiercePharma: #ICYMI yesterday: $BMY leapfrogs Merck with Opdivo approval in lung cancer. Story | Follow @FiercePharma

@EricPFierce: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. News | Follow @EricPFierce

@CarlyHFierce: J&J, Merck to advance #Ebola vaccines in Africa, but their fate rests in WHO's hands. More | Follow @CarlyHFierce

> Actavis ($ACT) lost an intellectual property fight over its osteoporosis med Atelvia, as a U.S. district judge invalidated two key patents; the company says it's reviewing an appeal. Release

> The California Supreme Court heard arguments in a "pay-for-delay" case involving Bayer and its alleged attempts to pay several generics makers to hold off on their copies of the antibiotic Cipro. Report

> Local officials in Hillsborough County, FL, approved $2.1 million in incentives to lure Johnson & Johnson ($JNJ) and 700 new jobs to the area; the county incentives add to $7 million previously approved by the state. Report

> Pharma industry reps told the Irish health committee Oireachtas that drug prices in the country are on par with those in other European countries, amid talks about a new government pricing contract. Report

> A New York federal judge ordered Novartis ($NVS) to hand over unredacted documents by March 13 in a False Claims Act suit over alleged kickbacks to pharmacies. Report

Medical Device News

@FierceMedDev: Micro-cap TearLab gets $35M in debt to get to breakeven on dry eye test. More | Follow @FierceMedDev

@VarunSaxena2: @AdvaMedUpdate calls for more appropriate medical device reimbursement in Japan - FierceMedicalDevices. Story | Follow @VarunSaxena2

@EmilyWFierce: OpGen eyes IPO worth up to $37M for drug-resistant bacteria genetic Dx. FierceDiagnostics article | Follow @EmilyWFierce

> AdvaMed calls for 'more appropriate' medical device reimbursement in Japan. News

> Startup raises $11.7M to make laparoscopic procedures clearer. Item

Biotech News

@FierceBiotech: Biotech upstart Tricida banks $30M for its kidney drug with OrbiMed in tow. Story | Follow @FierceBiotech

@JohnCFierce: Interested in Asian biopharma? Get the latest from @FiercePharmAsia. Newsletter | Follow @JohnCFierce

@DamianFierce: Via @Reuters, it's March 5 and biopharma deal dollars have already topped 2011. Article | Follow @DamianFierce

> Surprised, stunned and supportive: Analysts assess AbbVie's $21B Pharmacyclics deal. Editor's Corner

> Summit pulls off a downsized IPO for its DMD drug. Story

Pharma Asia News

> Major policy shift on costs and safety views as China moves to lift price controls on drugs. News

> Denovo Biopharma eyes China trial of licensed Eli Lilly neuroscience drug. Article

> Indonesia gains momentum as drug firms eye second year of phased national insurance. Item

> Big Pharma bodies ask China FDA to review comparability in biosimilar approval guidelines. More

> Hutchison China MediTech eyes first modern drug approval in China next year with Eli Lilly candidate. Report

Vaccines News

> Pfizer scores new Prevenar indication in Europe. Article

> Bristol-Myers bets $1B on Bavarian Nordic cancer vaccine. News

> J&J, Merck to advance Ebola vaccines in Africa, but their fate rests in WHO's hands. Story

> With 77 layoffs, Valeant gets to work squeezing costs from Dendreon. Item

> Aduro, BMS cancer vaccine combo to start Phase II. Report

Pharma Manufacturing News

> FDA aims to disseminate drug shortage info through app. More

> Generic drugmaker snaps up Lockheed site with big expansion plans. Article

> Jordan's MS Pharma gets $30M to expand manufacturing there. Report

> FDA campaign against use of foreign-made cancer drugs rolls up another doctor. Story

> Patheon buys specialty API maker IRIX. News

And Finally... Anticholinergic drugs, which include commonly used OTC remedies such as Benadryl, might be linked to a higher risk of pneumonia. Report

Suggested Articles

The lawsuit is part of a years-long battle between the Cochrane Collaboration and Roche around Tamiflu's use against pandemic influenza.

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

Sanofi's Dupixent is set to reach $12.5 billion in peak sales, Jefferies analysts wrote, affirming CEO Paul Hudson's focus on the immunology med.